AstraZeneca’s high-profile SGLT2 diabetes med Farxiga is looking at a bright future with big FDA decisions in heart failure and kidney disease right around the corner. Now, the British drugmaker is testing it as a potential coronavirus therapy, too. More:
read moreThe proposed merger between Mylan and Pfizer’s Upjohn unit, though facing a delay due to the COVID-19 pandemic, has won EU antitrust clearance—but not without conditions. Upjohn’s top-selling drugs Lyrica, Xalatan and Xalacom, among others, came under scrutiny in certain
read moreIn the hunt for a COVID-19 therapy, some researchers have hit upon a combination of antimalarial hydroxychloroquine and antibiotic azithromycin as a potential answer. So far, clinical results have been mixed at best—but demand for azithromycin has still been sky-high, and
read moreAs the COVID-19 pandemic trounced markets around the world, most of biopharma’s biggest companies saw their market capitalizations fall in the first quarter. There were a few exceptions, including Gilead, Regeneron and Roche, all of which gained on a combination
read moreDARE-19 will determine whether Farxiga can hold back disease progression and reduce the risk of clinical complications and death More: AZ, Saint Luke's begin testing Farxiga for COVID-19 Source: News
read moreForty percent of pharmacists surveyed said they were unable to maintain social distancing from patients More: Pharmacists warn of issues with social distancing, PPE Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals